Analyst IMS Investment Management Services’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $221K | Hold |
1,208
| – | – | 0.01% | 140 |
|
|
2025
Q4 | $213K | Buy |
+1,208
| New | +$197K | 0.01% | 125 |
|
|
2025
Q2 | – | Sell |
-1,527
| Closed | -$209K | – | 130 |
|
|
2025
Q1 | $209K | Hold |
1,527
| – | – | 0.01% | 131 |
|
|
2024
Q4 | $234K | Hold |
1,527
| – | – | 0.01% | 127 |
|
|
2024
Q3 | $296K | Hold |
1,527
| – | – | 0.01% | 124 |
|
|
2024
Q2 | $354K | Hold |
1,527
| – | – | 0.01% | 111 |
|
|
2024
Q1 | $329K | Buy |
1,527
+39
| +3% | +$9.13K | 0.01% | 99 |
|
|
2023
Q4 | $385K | Hold |
1,488
| – | – | 0.02% | 85 |
|
|
2023
Q3 | $384K | Hold |
1,488
| – | – | 0.02% | 82 |
|
|
2023
Q2 | $420K | Hold |
1,488
| – | – | 0.03% | 76 |
|
|
2023
Q1 | $409K | Hold |
1,488
| – | – | 0.03% | 76 |
|
|
2022
Q4 | $411K | Hold |
1,488
| – | – | 0.04% | 84 |
|
|
2022
Q3 | $393K | Hold |
1,488
| – | – | 0.04% | 81 |
|
|
2022
Q2 | $303K | Hold |
1,488
| – | – | 0.03% | 89 |
|
|
2022
Q1 | $313K | Sell |
1,488
-84
| -5% | -$18.3K | 0.03% | 92 |
|
|
2021
Q4 | $377K | Hold |
1,572
| – | – | 0.04% | 93 |
|
|
2021
Q3 | $445K | Hold |
1,572
| – | – | 0.05% | 89 |
|
|
2021
Q2 | $544K | Sell |
1,572
-680
| -30% | -$206K | 0.07% | 81 |
|
|
2021
Q1 | $629K | Hold |
2,252
| – | – | 0.08% | 78 |
|
|
2020
Q4 | $552K | Hold |
2,252
| – | – | 0.09% | 75 |
|
|
2020
Q3 | $639K | Hold |
2,252
| – | – | 0.13% | 70 |
|
|
2020
Q2 | $602K | Hold |
2,252
| – | – | 0.14% | 65 |
|
|
2020
Q1 | $713K | Sell |
2,252
-2,806
| -55% | -$852K | 0.23% | 51 |
|
|
2019
Q4 | $1.5M | Sell |
5,058
-1,400
| -22% | -$388K | 0.41% | 39 |
|
|
2019
Q3 | $1.49M | Hold |
6,458
| – | – | 0.44% | 37 |
|
|
2019
Q2 | $1.51M | Sell |
6,458
-415
| -6% | -$95.8K | 0.45% | 39 |
|
|
2019
Q1 | $1.62M | Sell |
6,873
-8,573
| -56% | -$2.7M | 0.5% | 35 |
|
|
2018
Q4 | $4.61K | Buy |
15,446
+7,683
| +99% | +$2.45M | 0.74% | 20 |
|
|
2018
Q3 | $2.75K | Sell |
7,763
-469
| -6% | -$161K | 0.44% | 25 |
|
|
2018
Q2 | $2.38M | Sell |
8,232
-82
| -1% | -$23.1K | 0.73% | 29 |
|
|
2018
Q1 | $2.28M | Sell |
8,314
-135
| -2% | -$41.9K | 0.72% | 31 |
|
|
2017
Q4 | $2.69M | Sell |
8,449
-226
| -3% | -$72.5K | 0.82% | 29 |
|
|
2017
Q3 | $2.69M | Sell |
8,675
-30
| -0.3% | -$8.88K | 0.88% | 30 |
|
|
2017
Q2 | $2.36M | Sell |
8,705
-100
| -1% | -$26.4K | 0.84% | 30 |
|
|
2017
Q1 | $2.39M | Buy |
8,805
+108
| +1% | +$30.5K | 0.93% | 27 |
|
|
2016
Q4 | $2.47M | Sell |
8,697
-539
| -6% | -$160K | 1.08% | 24 |
|
|
2016
Q3 | $2.89M | Buy |
9,236
+127
| +1% | +$37.6K | 1.22% | 20 |
|
|
2016
Q2 | $2.2M | Sell |
9,109
-344
| -4% | -$90.7K | 0.93% | 26 |
|
|
2016
Q1 | $2.46M | Sell |
9,453
-373
| -4% | -$98.5K | 1.06% | 28 |
|
|
2015
Q4 | $3.01M | Buy |
9,826
+815
| +9% | +$234K | 1.26% | 24 |
|
|
2015
Q3 | $2.63M | Buy |
9,011
+3,714
| +70% | +$1.23M | 1.11% | 31 |
|
|
2015
Q2 | $2.14M | Buy |
5,297
+712
| +16% | +$286K | 0.83% | 37 |
|
|
2015
Q1 | $1.94M | Buy |
4,585
+3,833
| +510% | +$1.51M | 0.75% | 38 |
|
|
2014
Q4 | $255K | Buy |
+752
| New | +$243K | 0.1% | 89 |
|
Other funds holding BIIB
VCM
VPM
Analyst IMS Investment Management Services's BIIB Position: Q1 2026 in Review
Analyst IMS Investment Management Services held its Biogen (BIIB) position steady in Q1 2026 at 1,208 shares worth $221K. The position accounts for 0.01% of the portfolio, ranked #140.
Analyst IMS Investment Management Services first reported a position in BIIB in Q4 2014 and has held it in 44 quarters since. The position peaked at $3.01M in Q4 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Analyst IMS Investment Management Services held 1,208 shares of Biogen worth $221K as of Q1 2026.
- Analyst IMS Investment Management Services left its Biogen share count unchanged in Q1 2026.
- Biogen made up 0.01% of Analyst IMS Investment Management Services's portfolio in Q1 2026, its #140 holding.
- Analyst IMS Investment Management Services first reported a position in Biogen in Q4 2014 and has held it in 44 quarters since.
- Analyst IMS Investment Management Services's Biogen position peaked at $3.01M in Q4 2015.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Analyst IMS Investment Management Services's 13F filing for Q1 2026, filed 23 Apr 2026.